Barclays Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $630
Barclays analyst Luke Sergott maintains Thermo Fisher Scientific (NYSE:TMO) with a Overweight and raises the price target from $570 to $630.
$1000 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth This Much Today
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 15 years by 9.62% on an annualized…
9 Analysts Have This to Say About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE:TMO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…
Here’s How Much $100 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth Today
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 13.74% on an annualized…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
$1000 Invested In Thermo Fisher Scientific 5 Years Ago Would Be Worth This Much Today
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 5 years by 15.77% on an annualized…
FDA Grants De Novo Classification To HLA Typing Test For Use As A Companion Diagnostic With A T Cell Receptor Therapy For Metastatic Or Unresectable Uveal Melanoma
The SeCore CDx HLA Sequencing System is the first HLA typing test to receive marketing authorization by the FDA for use as a companion diagnostic
RBC Capital Initiates Coverage On Thermo Fisher Scientific with Outperform Rating, Announces Price Target of $661
RBC Capital analyst Conor McNamara initiates coverage on Thermo Fisher Scientific (NYSE:TMO) with a Outperform rating and announces Price Target of $661.
7 Analysts Have This to Say About Thermo Fisher Scientific
Over the past 3 months, 7 analysts have published their opinion on Thermo Fisher Scientific (NYSE:TMO) stock. These…